• 1
    Chan JK, Jaffe ES, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In: JaffeES, HarrisNL, SteinH, VardimanJW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2001; 2047.
  • 2
    Chan JK, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: SwerdlowSH, CampoE, HarrisNL et al. , eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008; 2858.
  • 3
    Jaffe ES, Chan JK, Su IJ et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 10311.
  • 4
    Gaal K, Sun NC, Hernandez AM, Arber DA. Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol 2000; 24: 15117.
  • 5
    Ko YH, Kim CW, Park CS et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998; 83: 80612.
  • 6
    Kang YK, Kim BS, Kim TW et al. Clinicopathologic characteristics of Korean non-Hodgkin’s lymphomas based on REAL classification. Cancer Res Treat 1999; 31: 64152.
  • 7
    Kim TM, Lee SY, Jeon YK et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008; 19: 147784.
  • 8
    Li YX, Fang H, Liu QF et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood 2008; 112: 305764.
  • 9
    Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113: 39317.
  • 10
    Li YX, Liu QF, Fang H et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 2009; 15: 290512.
  • 11
    Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19: 218694.
  • 12
    Lee SY, Park K, Ryoo BY et al. Korean multicenter study of extranodal NK/T-cell lymphoma: failure of Ann Arbor staging in predicting prognosis. Seoul, Korea: The 29th World Congress of the International Society of Hematology, 2002.
  • 13
    Lee J, Park YH, Kim WS et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005; 41: 14028.
  • 14
    Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 18290.
  • 15
    Cuadra-Garcia I, Proulx GM, Wu CL et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol 1999; 23: 135669.
  • 16
    Liang R, Todd D, Chan TK et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995; 13: 66670.
  • 17
    Cheung MM, Chan JK, Lau WH et al. Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 707.
  • 18
    Kim GE, Cho JH, Yang WI et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 5463.
  • 19
    Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 6128.
  • 20
    Oshimi K, Kawa K, Nakamura S et al. NK-cell neoplasms in Japan. Hematology 2005; 10: 23745.
  • 21
    Lee J, Kim WS, Park YH et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 2005; 92: 122630.
  • 22
    Ko YH, Cho EY, Kim JE et al. NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status. Histopathology 2004; 44: 4809.
  • 23
    Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 412430.
  • 24
    Li YX, Yao B, Jin J et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24: 1819.
  • 25
    Pagano L, Gallamini A, Trape G et al. NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey. Ann Oncol 2006; 17: 794800.
  • 26
    Kim TM, Park YH, Lee SY et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106: 378590.
  • 27
    Kim SJ, Kim BS, Choi CW et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 2007; 18: 13827.
  • 28
    Aviles A, Diaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000; 22: 21520.
  • 29
    Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 21621.
  • 30
    You JY, Chi KH, Yang MH et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004; 15: 61825.
  • 31
    Robbins KT, Fuller LM, Vlasak M et al. Primary lymphomas of the nasal cavity and paranasal sinuses. Cancer 1985; 56: 8149.
  • 32
    Logsdon MD, Ha CS, Kavadi VS, Cabanillas F, Hess MA, Cox JD. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997; 80: 47788.
  • 33
    Shim SJ, Yang WI, Shin E et al. Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 2007; 67: 318.
  • 34
    Lin CW, Chen YH, Chuang YC, Liu TY, Hsu SM. CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Blood 2003; 102: 262331.
  • 35
    Bossard C, Belhadj K, Reyes F et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 2007; 109: 21839.
  • 36
    Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 2439.
  • 37
    Huang WT, Chang KC, Huang GC et al. Bone marrow that is positive for Epstein–Barr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica 2005; 90: 10639.
  • 38
    Lee J, Suh C, Huh J et al. Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res 2007; 13: 32504.
  • 39
    Kim WY, Jeon YK, Kim TM et al. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009; doi: DOI: 10.1093/annonc/mdp056.
  • 40
    Kako S, Izutsu K, Ota Y et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007; 18: 168590.
  • 41
    Suh C, Kang YK, Roh JL et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 2008; 49: 17839.
  • 42
    Kim WS, Song SY, Ahn YC et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 34952.
  • 43
    Ribrag V, Ell Hajj M, Janot F et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001; 15: 11236.
  • 44
    Shikama N, Izuno I, Oguchi M et al. Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Radiology 1997; 204: 46770.
  • 45
    Kim BS, Kim TY, Kim CW et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy – result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 2003; 42: 77983.
  • 46
    Lee KW, Yun T, Kim DW et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/− radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 2006; 47: 127482.
  • 47
    Chan JK, Sin VC, Wong KF et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 450113.
  • 48
    Kwong YL, Chan AC, Liang R et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 8219.
  • 49
    Nagafuji K, Fujisaki T, Arima F, Ohshima K. l-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 44750.
  • 50
    Yong W, Zheng W, Zhang Y et al. l-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003; 78: 1637.
  • 51
    Yong W, Zheng W, Zhu J et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of l-asparaginase based regimen, and prognostic factors. Hematol Oncol 2006; 24: 2832.
  • 52
    Ando M, Sugimoto K, Kitoh T et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 2005; 130: 8608.
  • 53
    Yamaguchi M, Suzuki R, Kwong YL et al. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 101620.
  • 54
    Kim K, Ryu K, Ko Y, Park C. Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Haematol 2005; 131: 5966.
  • 55
    Shen L, Au WY, Guo T et al. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood 2007; 110: 46970.
  • 56
    Lee J, Suh C, Kang HJ et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008; 19: 207983.
  • 57
    Yong W, Zheng W, Zhu J et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2009; 88: 64752.
  • 58
    Zhang XX, Xie CH, Xu Y et al. Salvage treatment improved survival of patients with relapsed extranodal natural killer/t-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 2009; 74: 74752.
  • 59
    Murashige N, Kami M, Kishi Y et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 5617.
  • 60
    Au WY, Lie AK, Liang R et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14: 16736.
  • 61
    Lee J, Au WY, Park MJ et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008; 14: 135664.
  • 62
    Kim BS, Kim DW, Im SA et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol 2009; 20: 1218.
  • 63
    Nagato T, Kobayashi H, Kishibe K et al. Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients. Clin Cancer Res 2005; 11: 82507.
  • 64
    Jeon YK, Park CH, Kim KY et al. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein–Barr virus-positive NK/T-cell lymphoma by Akt down-regulation. J Pathol 2007; 213: 1709.
  • 65
    Coppo P, Gouilleux-Gruart V, Huang Y et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma. Leukemia 2009; doi: DOI: 10.1038/leu.2009.91.